Molybdenum compounds for use in the treatment of cyanide poisoning

1. A compound according to the following formula:

Wherein

X is S or a bond; and

R 1 , R 2 , and R 3 independently or together are one or more of the ligands selected from: a mono- or disaccharide having 3 to 12 carbon atoms, a mono- or di-carboxylic acid having 1 to 5 carbon atoms, which may be substituted with O, S, CH 3 S— or N, a thiocarboxylic acid having 1 to 5 carbon atoms, a primary, secondary or tertiary amide having 1 to 5 carbon atoms, wherein the side chains attached to the nitrogen is an alkyl having 1 to 5 carbon atoms, threonine, serine, glutamate, malate, oxalate, mercapto succinate, cyanide thiocyanate, thiosulfate, or sulfite; and wherein R 3 may be an electron pair.

2. The compound according to claim 1 , wherein X is a bond.

3. The compound according to claim 1 , with the formula:

wherein R 1 , R 2 , and R 3 independently or taken together are one or more of the ligands selected from the group consisting of: threonine, serine, glutamate, malate, oxalate, mercapto succinate, cyanide, thiocyanate, thiosulfate and sulfite.

4. The compound according to claim 3 , wherein the ligand is threonine.

5. The compound according to claim 1 , wherein the molybdenum compound is in the form of a pharmaceutically acceptable salt.

6. A pharmaceutical composition comprising the compound according to claim 1 .

7. A method of treating cyanide poisoning in a mammal, said method comprising administering a therapeutically effective amount of a compound as defined in claim 1 .

8. The method according to claim 7 , wherein the mammal is human.

9. A pharmaceutical composition comprising a compound according to the following formula:

Wherein

X is S or a bond; and

R 1 , R 2 , and R 3 independently or together are one or more of the ligands selected from: a mono- or disaccharide having 3 to 12 carbon atoms, a mono- or di-carboxylic acid having 1 to 5 carbon atoms, which may be substituted with O, S, CH 3 S— or N, a thiocarboxylic acid having 1 to 5 carbon atoms, a primary, secondary or tertiary amide having 1 to 5 carbon atoms, wherein the side chains attached to the nitrogen is an alkyl having 1 to 5 carbon atoms, threonine, serine, glutamate, malate, oxalate, mercapto succinate, cyanide, thiocyanate, thiosulfate or sulfite; and wherein R 3 may be an electron pair.

10. The pharmaceutical composition according to claim 9 , wherein X is a bond.

11. The pharmaceutical composition according to claim 10 , wherein R 1 , R 2 , and R 3 taken together is one of the ligands selected from the group consisting of: threonine, serine, glutamate, malate, oxalate, mercapto succinate, cyanide, thiocyanate, thiosulfate and sulfite.

12. The pharmaceutical composition according to claim 11 , wherein the ligand is threonine.

13. The pharmaceutical composition according to claim 9 , wherein the molybdenum compound is in the form of a pharmaceutically acceptable salt.

14. The pharmaceutical composition according to claim 13 , wherein the molybdenum compound is in the form of a salt having a cation selected from the group consisting of: sodium, potassium, and R 4 N, wherein R is hydrogen, glucosamine, ethanolamine, diethanolamine, triethanolamine (TEA), tromethamine (TRIS) or N-methylaminoethanol.

15. The pharmaceutical composition according to claim 9 , further comprising a sulfur source.

16. The pharmaceutical composition according to claim 15 , wherein the sulfur source is selected from the group consisting of: sulfur, thiosulfate, ammonium sulphide, dithiothreitol (DTT), trithiothreitol, gluthathi one, and dibenzyl tri sulfide (DTS).

17. The pharmaceutical composition according to claim 16 , wherein the sulfur source is a salt selected from the group consisting of sodium thiosulfate and potassium thiosulfate.

18. A method of treating cyanide poisoning in a mammal, said method comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 9 .

19. The method according to claim 18 , wherein the mammal is human.